Development and evaluation of (89)Zr-trastuzumab for clinical applications

OBJECTIVE(S): Due to the suitable physical characteristics of (89)Zr as a PET radionuclide and affinity of Trastuzumab monoclonal antibody against HER2, [(89)Zr]Zr-Trastuzumab was prepared and went through preclinical evaluations for ultimate human applications. METHODS: (89)Zr was produced by using...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohammadpour-Ghazi, Fatemeh, Yousefnia, Hassan, Divband, GhasemAli, Zolghadri, Samaneh, Alirezapour, Behrouz, Shakeri, Fatemeh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mashhad University of Medical Sciences 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10261689/
https://www.ncbi.nlm.nih.gov/pubmed/37324228
http://dx.doi.org/10.22038/AOJNMB.2022.68093.1471

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10261689/
https://www.ncbi.nlm.nih.gov/pubmed/37324228
http://dx.doi.org/10.22038/AOJNMB.2022.68093.1471

Ejemplares similares